US legislative update: takeaways for European pharma
Keith A Zullow and Jenny J Zhang examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma.
Stay updated with breaking news from Stop Stalling Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Keith A Zullow and Jenny J Zhang examine upcoming US pharmaceutical regulation and how, if passed, it could impact European pharma/biopharma.
The Big Molecule Watch is monitoring pending legislation in Congress that relates to biosimilars and biologics. In this post, we check in on the status of two currently pending bills...
2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology...
Congress passed – and the President signed into law – a short-term continuing resolution (CR) to avoid a government shutdown and fund government operations through December 3...